Morgan Stanley Adaptive Biotechnologies Corp Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Adaptive Biotechnologies Corp stock. As of the latest transaction made, Morgan Stanley holds 1,297,944 shares of ADPT stock, worth $23.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,297,944

Previous 1,125,261 15.35%

Holding current value

$23.1 Million

Previous $8.36 Million 80.87%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$6.83 - $12.16 $1.18 Million - $2.1 Million	172,683 Added 15.35%	1,297,944 $15.1 Million
Q1 2025 May 15, 2025	SELL	$6.07 - $8.66 $416,244 - $593,850	-68,574 Reduced 5.74%	1,125,261 $8.36 Million
Q4 2024 Feb 14, 2025	BUY	$4.37 - $6.78 $636,722 - $987,866	145,703 Added 13.9%	1,193,835 $7.16 Million
Q3 2024 May 14, 2025	BUY	$3.37 - $5.12 $1.79 Million - $2.72 Million	531,672 Added 102.95%	1,048,132 $5.37 Million
Q3 2024 Nov 14, 2024	BUY	$3.37 - $5.12 $1.79 Million - $2.72 Million	531,672 Added 102.95%	1,048,132 $5.37 Million
Q2 2024 May 14, 2025	SELL	$2.34 - $3.96 $1.59 Million - $2.68 Million	-677,375 Reduced 56.74%	516,460 $1.87 Million
Q2 2024 Oct 17, 2024	SELL	$2.34 - $3.96 $357,247 - $604,573	-152,670 Reduced 22.82%	516,460 $1.87 Million
Q2 2024 Aug 14, 2024	SELL	$2.34 - $3.96 $357,247 - $604,573	-152,670 Reduced 22.82%	516,460 $1.87 Million
Q1 2024 Oct 17, 2024	BUY	$2.88 - $4.8 $439,689 - $732,816	152,670 Added 29.56%	669,130 $2.15 Million
Q1 2024 Aug 16, 2024	SELL	$2.88 - $4.8 $791,046 - $1.32 Million	-274,669 Reduced 29.1%	669,130 $2.15 Million
Q1 2024 May 15, 2024	SELL	$2.88 - $4.8 $791,046 - $1.32 Million	-274,669 Reduced 29.1%	669,130 $2.15 Million
Q4 2023 Aug 16, 2024	BUY	$3.46 - $5.33 $1.48 Million - $2.28 Million	427,339 Added 82.74%	943,799 $4.62 Million
Q4 2023 Feb 13, 2024	BUY	$3.46 - $5.33 $1.86 Million - $2.87 Million	539,016 Added 133.16%	943,799 $4.62 Million
Q3 2023 Nov 15, 2023	SELL	$5.07 - $8.44 $1.3 Million - $2.16 Million	-255,730 Reduced 38.72%	404,783 $2.21 Million
Q2 2023 Aug 14, 2023	SELL	$6.19 - $8.78 $330,601 - $468,931	-53,409 Reduced 7.48%	660,513 $4.43 Million
Q1 2023 May 15, 2023	SELL	$7.8 - $10.11 $5.41 Million - $7.01 Million	-693,768 Reduced 49.28%	713,922 $6.3 Million
Q4 2022 Feb 14, 2023	BUY	$6.26 - $9.34 $2.42 Million - $3.61 Million	386,229 Added 37.81%	1,407,690 $10.8 Million
Q3 2022 Nov 14, 2022	SELL	$6.5 - $12.67 $818,382 - $1.6 Million	-125,905 Reduced 10.97%	1,021,461 $7.27 Million
Q2 2022 Oct 27, 2022	BUY	$6.4 - $14.73 $4.1 Million - $9.43 Million	640,112 Added 126.19%	1,147,366 $9.28 Million
Q2 2022 Aug 15, 2022	BUY	$6.4 - $14.73 $4.1 Million - $9.43 Million	640,112 Added 126.19%	1,147,366 $9.28 Million
Q1 2022 Oct 27, 2022	SELL	$10.12 - $28.9 $6.48 Million - $18.5 Million	-640,112 Reduced 55.79%	507,254 $7.04 Million
Q1 2022 May 13, 2022	BUY	$10.12 - $28.9 $1.17 Million - $3.34 Million	115,575 Added 29.51%	507,254 $7.04 Million
Q4 2021 Feb 14, 2022	SELL	$25.17 - $36.85 $1.84 Million - $2.69 Million	-72,950 Reduced 15.7%	391,679 $11 Million
Q3 2021 Nov 15, 2021	BUY	$30.02 - $39.87 $13.9 Million - $18.5 Million	464,629 New	464,629 $15.8 Million

Others Institutions Holding ADPT

# of Institutions

267

Shares Held

149M

Call Options Held

168K

Put Options Held

25.2K

View Full List

About Adaptive Biotechnologies Corp

Ticker ADPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 142,872,992
Market Cap $2.55B
Description
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signal...

More about ADPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account